Therefore, we conclude that the expression level of TNFRSF9 in TI-Tregs is a novel biomarker that can predict the prognosis of anticancer treatment and response to anti-PD-1 immunotherapy in human lung cancer. The gene discussed is PDCD1; the disease is lung carcinoma.